Hubei Jumpcan Pharmaceutical (600566.SZ) Subsidiary Signs Exclusive Commercialization Agreement with Puqi Pharmaceutical

Stock News

02/02

Hubei Jumpcan Pharmaceutical Co.,Ltd. (600566.SZ) announced that its wholly-owned subsidiary, Jichuan Pharmaceutical Group Co., Ltd. ("Jichuan Limited"), has entered into an exclusive commercialization agreement with Beijing Puqi Pharmaceutical Technology Co., Ltd. ("Puqi Pharmaceutical").

The agreement grants Jichuan Limited exclusive rights to commercialize Puqi Pharmaceutical's Pumeixitinib (PG-011) nasal spray in China for the duration of the collaboration.

Jichuan Limited will pay Puqi Pharmaceutical an exclusive commercialization rights fee of up to a maximum of RMB 100 million (including tax).

According to the announcement, Pumeixitinib (PG-011) is a JAK1/2 inhibitor with independent intellectual property rights, developed for the treatment of allergic rhinitis.

Upon completion of the transaction, the company will further enhance the diversity of its product pipeline, which is conducive to the sustainable development of its business.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1192368771"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1192368771\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1192368771?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-02 18:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1192368771","market":"other","top_or_hot":-1,"title":"Hubei Jumpcan Pharmaceutical (600566.SZ) Subsidiary Signs Exclusive Commercialization Agreement with Puqi Pharmaceutical","media":"Stock News","content":"<p>Hubei Jumpcan Pharmaceutical Co.,Ltd. (600566.SZ) announced that its wholly-owned subsidiary, Jichuan Pharmaceutical Group Co., Ltd. (\"Jichuan Limited\"), has entered into an exclusive commercialization agreement with Beijing Puqi Pharmaceutical Technology Co., Ltd. (\"Puqi Pharmaceutical\").</p>\n<p>The agreement grants Jichuan Limited exclusive rights to commercialize Puqi Pharmaceutical's Pumeixitinib (PG-011) nasal spray in China for the duration of the collaboration.</p>\n<p>Jichuan Limited will pay Puqi Pharmaceutical an exclusive commercialization rights fee of up to a maximum of RMB 100 million (including tax).</p>\n<p>According to the announcement, Pumeixitinib (PG-011) is a JAK1/2 inhibitor with independent intellectual property rights, developed for the treatment of allergic rhinitis.</p>\n<p>Upon completion of the transaction, the company will further enhance the diversity of its product pipeline, which is conducive to the sustainable development of its business.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hubei Jumpcan Pharmaceutical (600566.SZ) Subsidiary Signs Exclusive Commercialization Agreement with Puqi Pharmaceutical</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHubei Jumpcan Pharmaceutical (600566.SZ) Subsidiary Signs Exclusive Commercialization Agreement with Puqi Pharmaceutical\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2026-02-02 18:35</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Hubei Jumpcan Pharmaceutical Co.,Ltd. (600566.SZ) announced that its wholly-owned subsidiary, Jichuan Pharmaceutical Group Co., Ltd. (\"Jichuan Limited\"), has entered into an exclusive commercialization agreement with Beijing Puqi Pharmaceutical Technology Co., Ltd. (\"Puqi Pharmaceutical\").</p>\n<p>The agreement grants Jichuan Limited exclusive rights to commercialize Puqi Pharmaceutical's Pumeixitinib (PG-011) nasal spray in China for the duration of the collaboration.</p>\n<p>Jichuan Limited will pay Puqi Pharmaceutical an exclusive commercialization rights fee of up to a maximum of RMB 100 million (including tax).</p>\n<p>According to the announcement, Pumeixitinib (PG-011) is a JAK1/2 inhibitor with independent intellectual property rights, developed for the treatment of allergic rhinitis.</p>\n<p>Upon completion of the transaction, the company will further enhance the diversity of its product pipeline, which is conducive to the sustainable development of its business.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"159938","symbol_name":"醫藥","start_time":0,"source_url":"","article_id":"1192368771","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1192368771","pubTimestamp":1770028508,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Hubei Jumpcan Pharmaceutical Co.,Ltd. (600566.SZ) announced that its wholly-owned subsidiary, Jichuan Pharmaceutical Group Co., Ltd. (\"Jichuan Limited\"), has entered into an exclusive...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","600566":"济川药业","09939":"开拓药业-B","BK0028":"国家队","BK0239":"医药制造","BK0201":"可转债","BK1515":"抗疫概念","BK0188":"融资融券","BK1574":"生物医药B类股","BK1161":"生物科技","BK0077":"质押式回购","BK0012":"证金概念","BK0187":"一线龙头"},"translate_title":"湖北跃普康制药（600566.SZ）子公司与普祺制药签署独家商业化协议","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"600566":1,"09939":1},"content_text":"Hubei Jumpcan Pharmaceutical Co.,Ltd. (600566.SZ) announced that its wholly-owned subsidiary, Jichuan Pharmaceutical Group Co., Ltd. (\"Jichuan Limited\"), has entered into an exclusive commercialization agreement with Beijing Puqi Pharmaceutical Technology Co., Ltd. (\"Puqi Pharmaceutical\").\nThe agreement grants Jichuan Limited exclusive rights to commercialize Puqi Pharmaceutical's Pumeixitinib (PG-011) nasal spray in China for the duration of the collaboration.\nJichuan Limited will pay Puqi Pharmaceutical an exclusive commercialization rights fee of up to a maximum of RMB 100 million (including tax).\nAccording to the announcement, Pumeixitinib (PG-011) is a JAK1/2 inhibitor with independent intellectual property rights, developed for the treatment of allergic rhinitis.\nUpon completion of the transaction, the company will further enhance the diversity of its product pipeline, which is conducive to the sustainable development of its business.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}